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Subtypes of Influenza 
T h e influenza virus is an RNA-containing enveloped 
virus. The envelope is covered wi th spikes of two types: 
hemagglutinin (H) and neuraminidase (N). There are at 
least three subtypes of influenza: influenza A, B, and C. 
Influenza C, which accounts for a small proport ion of 
common cold illnesses, wil l not be discussed further 
here. Alterations in the antigenic structure of the in-
fluenza viruses can lead to infection wi th variant strains 
of virus. As a result, infection wi th these variants may 
occur because of l imited resistance to these new strains 
in the populat ion at risk. 
There are two kinds of antigenic variation: antigenic 
dr i f t and antigenic shift. Antigenic dri f t , which occurs 
with both influenza A and B viruses, involves relatively 
minor changes wi th in the subtype in e i therthe H or N as 
a result of permutations. For example, antigenic dri f t is 
responsible for the H3N2 variants of influenza A virus: 
A/England/72, A/Port Chalmers/73, A/Scotland/74, A/ 
Victoria/75, and A/Texas/77. Because of the absence of 
antibody in the populat ion at risk, immunologic selec-
t ion can take place, and modif ied strains of virus can be 
transmitted f rom person to person. 
Antigenic shift refers to major changes of the entire 
surface protein, either H or N or both. The new H or N is 
renumbered to distinguish it f rom other types of in-
fluenza A (ie, H Q N I , H1N1, H2N2, etc.). Antigenic shift, 
wh ich is caused by genet ic recombina t ion or re-
assor tment , is t hough t to be responsib le for the 
periodic pandemics or widespread disease wi th in-
fluenza that occurs about every ten years. 
Prevention of Influenza 
Vaccines for influenza are between 70% and 85% effec-
tive in reducing attack rates (1). In general, influenza 
vaccine should be given in the fall of each year before 
influenza first appears dur ing the winter season. The 
vaccine is recommended for those at high risk for in-
fluenza infection and its complications. High-risk per-
sons include individuals over the age of 60 and patients 
with chronic underlying diseases of any type such as 
diabetes, obstructive lung disease, chronic renal dis-
ease, malignancy, or heart disease of any etiology (2). 
Persons who provide essential community services such 
as health care workers should also be vaccinated (3). 
The vaccine formulat ion is usually bivalent, containing 
antigens against two subtypes of influenza A virus. 
Recently, the vaccine has become trivalent, containing 
antigens for two types of influenza A and one of in-
fluenza B. The vaccine formulat ion is generally changed 
from year to year because of the antigenic shift of the 
influenza virus. 
The vaccine is relatively benign in terms of side effects. 
The major side effect is soreness at the injection site, 
which occurs in about 25% of those receiving the vac-
cine. A much smaller number wil l have fever, myalgias, 
orotherconst i tut ional symptoms last ingonlyafewdays. 
The Guillain-Barre syndrome, which was seen during 
the national immunizat ion program for swine f lu , has 
not been seen wi th subsequent vaccine formulations. 
An unwarranted fear of the Guillain-Barre syndrome 
has made it di f f icult for many vaccine programs to be 
carried out, especially among health care workers. Rec-
ommendat ions for inf luenza vaccine are publ ished 
yearly by the Centers for Disease Control in their Mor-
bidity and Mortal i ty Weekly Reports (2). 
Amantadine hydrochloride (Symmetrel) is also used as 
preventive therapy for influenza. This antiviral agent is 
effective in preventing u p t o 90% of influenza A, but not 
influenza B virus infections (4). Amantadine may be 
used alone wi thout vaccine dur ing an influenza epi-
demic, or it may be used in combinat ion with influenza 
vaccine. If used alone, the drug should be continued for 
the duration o f t he outbreak of influenza, usually five to 
six weeks. If used in combinat ion wi th influenza vac-
cine, it is usually given for two weeks whi le wait ing for a 
protective antibody titer to develop f rom vaccination. 
Some patients may have mi ld , reversible central ner-
vous system (CNS) side effects such as nervousness, 
insomnia, d i f f icu l ty concentrat ing or, rarely, night-
mares and hallucinations. Gastrointestinal symptoms 
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also occur. Our experience with amantadine has shown 
that compliance of ten is poor because of the gas-
trointestinal or other side effects. Therefore, the drug 
should probably be used in combination wi th the vac-
cine so that i tcan be given for as short a t ime as possible. 
The recommended dose for adults (200mg/day) should 
be taken in the morning in order to avoid any CNS side 
effects that might interfere wi th sleep if the drug were 
given in the evening. 
In general, the best preventive therapy for influenza 
remains vaccination, either alone in the fall or in com-
bination wi th amantadine if preventive measures are 
initiated after an outbreak of influenza occurs in the 
community. 
Recently, rimantadine hydrochlor ide, an amantadine 
analog, has been reported to be more active than aman-
tadine against influenza A virus in vi tro and against 
experimentally-induced influenza A infection in labora-
tory animals (5). In another study, r imantadine used 
prophylactically was associated wi th significantly fewer 
CNS side effects; this f inding suggests that rimantadine 
would be a reasonable alternative to amantadine once it 
has been approved by the Food and Drug Admin -
istration (6). 
Treatment 
Amantadine probably has its greatest uti l i ty in the ther-
apy of established infections wi th influenza virus. The 
drug, which is specif icfor influenza A viruses but not for 
influenza B viruses, results in more rapid defervescence 
and more rapid d iminut ion in systemic and respiratory 
symptoms (7). For max imum benef i t , amantadine 
should be initiated wi th in 48 hours of the onset of the 
symptoms of influenza A. The drug is probably under-
used because most physicians are not familiar wi th it, 
and they are not familiar wi th the fact that the drug is 
licensed by the Food and Drug Administrat ion both to 
treat and prevent influenza A infections. Our experi-
ence has been that compliance wi th amantadine is bet-
ter when it is used for treatment rather than prophylaxis 
since patients may be more motivated to take the drug 
when they are i l l . 
One problem with init iating amantadine therapy is rec-
ognizing the syndrome. In many places, virus isolation 
facilities are not readily available, and when they are, 
the results of virus isolation may take up to a week or 
more. Therefore, the physician must be able to recog-
nize the symptoms of influenza infection and initiate 
therapy based on clinical impression. When it is estab-
lished that influenza A virus is prevalent in the com-
munity, most persons wi th acute febri le respiratory or 
acute febrile undifferentiated illness can be assumed to 
have influenza A virus infect ion. It is important to re-
member that influenza is a disease primarily of the 
respiratory tract and not of the gastrointestinal tract. 
Gastrointestinal symptoms wi thout respiratory symp-
toms are rarely due to influenza virus. 
This is the era of antiviral chemotherapy. Many antiviral 
compounds are currently on the market and more are 
being developed. As rapid viral diagnostic techniques 
become available, the decision-making process used 
for bacterial infections wi l l also be applied to viral infec-
t ions. The physician should be aware of this new 
direction in virology and become familiar wi th these 
antiviral compounds and their use. 
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